Venture capital for
companies developing
innovative therapeutics

Strategy

Pureos Bioventures invests venture capital in private innovative drug development companies, with an emphasis on the next generation of biological drugs and drug formats. We strive to impact patients’ lives by advancing innovative treatments for severe diseases.

Portfolio

Our companies are developing innovative therapeutics for severe diseases and contitions. We are backing great teams with development programs that make a true difference for patients.

Acrivon Therapeutics

Acrivon Therapeutics is a clinical stage oncology company developing novel cancer drugs paired with companion diagnostics predicting treatment response and driving patient selection.

acrivon.com

Alentis Therapeutics

AlentisTherapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer.

alentis.ch

AM Pharma

AM-Pharma is a clinical stage biopharmaceutical company developing recombinant human Alkaline Phosphatase (recAP) as a potentially life-saving treatment of acute kidney injury and sepsis.

am-pharma.com

Araris Biotech

Araris Biotech is a spin-off from the PSI / ETH Zurich developing next generation antibody-drug conjugates for the treatment of different cancers.

ararisbiotech.com

BaseLaunch

BaseLaunch is the Basel area-based incubator and accelerator that helps scientists and entrepreneurs to launch exceptional biotech companies in Switzerland.

baselaunch.ch

Corlieve Therapeutics

Corlieve Therapeutics is a French biotech company, developing transformational therapies for neurological diseases. The lead program is a treatment for drug resistant temporal lobe epilepsy leveraging innovative gene therapy approaches. In June 2021, Corlieve was acquired by uniQure for up to € 250 million. 

corlieve.com

Eyevensys

Eyevensys is a clinical-stage ophthalmology biotech company developing non-viral gene therapies for severe eye diseases using its ocular electro-transfection platform technology.

eyevensys.com

Hummingbird Bioscience

Hummingbird Bioscience is a clinical-stage biopharmaceutical company focused on developing precision monoclonal antibodies against difficult targets for better therapies in different cancer indications.

hummingbirdbioscience.com

ImCheck Therapeutics

ImCheck Therapeutics is developing novel antibody therapeutics that target butyrophilin checkpoint molecules to activate immune cells for the treatment of cancer.

imchecktherapeutics.com

Lava Therapeutics

Lava Therapeutics is developing bi- specific gamma- delta T-cell engagers for the treatment of hematological and solid cancers. In March 2021, Lava went public at the NASDAQ.

lavatherapeutics.com

NovaGo Therapeutics

NovaGo Therapeutics is a Swiss start-up dedicated to the development of regenerative therapies for diseases in the eye and the central nervous system.

novagotherapeutics.com

River Renal

River Renal is a clinical-stage company developing novel therapies for orphan renal diseases.

Vico Therapeutics

Vico Therapeutics is a Dutch biotech company developing anti-sense oligonucleotides for treating rare severe neurological disorders with high unmet medical need.

vicotx.com

We are driven by the quest for
new and better medicines

Team

We are career venture capitalists, biotech founders, former pharma and biotech executives, research scientists, medical doctors, and experienced drug developers. What unites us is the passion for biotech start-ups, innovation and the quest for new and better medicines.

Dr. Dominik Escher
Managing Partner
Dr. Dominik Escher
Managing Partner

Dominik is a founding partner of Pureos and a co-founder and Executive Chairman of CDR-Life. He is also president of the Swiss Biotech Association. Previously, he was a founder and CEO of ESBATech, which was acquired in 2009 by Alcon (Novartis) for USD 589 million. As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novel antibody fragments from discovery to maturity, delivering multiple clinically successful products (e.g., Brolucizumab). Dominik obtained his PhD in Molecular Biology from the University of Zurich.


Dr. Klaus Breiner
Managing Partner
Dr. Klaus Breiner
Managing Partner

Klaus is a founding partner of Pureos and has been a venture capital investor since 2001, across different regions, companies stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Bio-pharmaceutical companies that Klaus has invested in include AM-Pharma, Alpex Pharma, Cadence Pharmaceuticals, Glycart Biotechnology, Hummingbird Bioscience, ImCheck Therapeutics and Vaximm. Before venture capital, Klaus was a researcher at ETH Zurich and a business consultant at Booz Allen & Hamilton. Klaus holds an MA in chemistry from the University of North Carolina, Chapel Hill, and a PhD in molecular biology from the University of Heidelberg (ZMBH).


Dr. Martin Münchbach
Managing Partner
Dr. Martin Münchbach
Managing Partner

Martin is a founding partner of Pureos and has been a venture capital investor since 1999, investing in life science companies across all stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Martin’s most successful investments and board assignments include Radius Health, Molecular Partners, Optimer, Axovan and Glycart. Martin is currently a BoD member at Ypsomed Holding, Alentis Therapeutics, binX Health, River Renal and SatoSea Oncology. Martin obtained his PhD in protein chemistry from the ETH Zurich and his MAS in Management, Technology, and Economics from ETH Zurich.


Dr. Ximing Ding
Associate
Dr. Ximing Ding
Associate

Ximing joined the Pureos Bioventures team in 2018. Prior to Pureos, he was Post-doc at the European Molecular Biology Laboratory in Heidelberg, Germany. As an Associate, Ximing is active in deal flow generation, investment due diligence, investment and exit transactions as well as fundraising support. Ximing is currently a BoD observer at Araris Biotech. Ximing obtained his PhD at the European Molecular Biology Laboratory and holds an MSc. in Biology at ETH Zurich.


Dr. Anne Grahl
Analyst
Dr. Anne Grahl
Analyst

Anne joined the Pureos Bioventures team in 2021. She has collected first venture capital experience as Analyst fellow at M Ventures, the corporate venture arm of Merck KGaA, in Amsterdam. Prior to that, Anne was Post-Doc at the University of Basel. Anne obtained her PhD in structural biology from the University of Basel and studied biochemistry and molecular biology at the University of Kiel and the University of Jena, in Germany, and at the University of York in the UK.


Nina Glüsing
Office Manager
Nina Glüsing
Office Manager

Nina is Office Manager & Team Assistant at Pureos Partners. After her studies of Applied Business Languages and International Management, Nina lived and worked for many years in Japan, China and the Philippines. After her return to Switzerland, Nina had various management assistant roles in different industries. Nina also teaches Yoga and bodytherapy techniques and joined Pureos in 2021.


Dr. Dragan Grabulovski
Venture Partner
Dr. Dragan Grabulovski
Venture Partner

Dragan was CSO and co-founder of Covagen AG, a Swiss biotech company focusing on bispecific antibodies and antibody alternatives. Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson acquired Covagen in 2014. Since 2015 Dragan is an independent advisor in pharmaceutical biotechnology, start-up coach at ETH Zurich and Innosuisse (Swiss Innovation Agency), board member and entrepreneur. Dragan received his master’s degree in pharmaceutical sciences and Doctor of Sciences from ETH Zurich.


Ian Metcalfe
Venture Partner
Ian Metcalfe
Venture Partner

Ian joined NovaGo Therapeutics as CEO in 2020. Before NovaGo, Ian worked as Chief Operating Officer for Corlieve Therapeutics, which was acquired by uniQure in July 2021. Prior to that, Ian held positions of increasing responsibility at both Roche and Nestlé, including Investor Relations, business development/M&A, Global Product Strategy, and late-stage Pharma Development. Ian’s earlier career involved his own start-up enterprise, playing a key role in Berna Biotech’s R&D group, and raising funds for the Sicilian based start-up Etna Biotech. Ian holds a 1st class degree in Applied biology (genetic engineering), and a master’s in marketing from UMIST.


Dr. Lars Nieba
Venture Partner
Dr. Lars Nieba
Venture Partner

Lars brings more than 20 years of leadership experience in the development of several pharmaceutical products and innovative technologies. Lars is Chief Technology Officer at Nordic Nanovector, a biotech company developing novel radio-immunoconjugates for treating cancers. Previously, Lars was VP and Strategic Product Lead at Bayer. Before that Lars held several leadership roles at F. Hoffmann-La Roche responsible for clinical supply planning, biologics technology and technical business development biologics. Lars gained his PhD from the Max-Planck-Institute for Biochemistry, Munich, and Institute for Biochemistry at the University of Zürich; he also holds an executive MBA from the University of St. Gallen, Switzerland.

Dr. Roberto Iacone, MD PhD
Venture Partner
Dr. Roberto Iacone, MD PhD
Venture Partner

Roberto is CEO of Alentis Therapeutics and a physician-scientist and biotech entrepreneur who has advanced several assets to early clinical development. He has strong translational medicine and strategic experience across rare diseases, fibrosis, immunology, and oncology. Prior to Alentis, Roberto was part of the leadership team which built Black Diamond Therapeutics from inception through multiple financing rounds and to a NASDAQ IPO, and Bright Peak Therapeutics. Prior to that he was heading rare diseases research at Roche. Roberto holds a PhD from TU Dresden, Germany and an MD from University of Naples Frederico II, Italy.


Dr. Omar Khwaja, MD PhD
Advisory Board
Dr. Omar Khwaja, MD PhD
Advisory Board

Omar is currently CMO at VectivBio, and was before that CMO and Head of Research and Development at Voyager Therapeutics. Previous to that, he was the Global Head of Rare Diseases and Neuroscience Translational Medicine at Roche, practiced medicine at Boston Children’s Hospital and was Chief Resident at Harvard Medical School. Dr. Khwaja received his MD and PhD in Human Molecular Genetics from the University of Cambridge, UK. He is a member of the Royal College of Physicians, serves as CMO for the Spinal Muscular Atrophy Foundation and is the Chair of the Scientific Advisory Board of the CDKL5 Forum.


Prof. Dr. Roger Nitsch
Advisory Board
Prof. Dr. Roger Nitsch
Advisory Board

Roger is co-founder, CEO and President of Neurimmune and a key opinion leader in neurodegenerative diseases. He is a pioneer in the development of therapeutic approaches for neurodegenerative diseases, and inventor and developer of aducanumab in partnership with Biogen, the first disease-modifying treatment and first approved therapy in more than two decades for Alzheimer disease. Roger is also professor at the Institute for Regenerative Medicine, University of Zurich, a Potamkin prize winner and member of the German Academy of Sciences. Roger obtained his medical doctor from the University of Heidelberg.


Prof. Dr. Bernd Seizinger
Advisory Board
Prof. Dr. Bernd Seizinger
Advisory Board

Bernd was the former President & CEO of GPC Biotech. He built the company from a pre-clinical stage to a NASDAQ listed, Phase 3 clinical stage oncology company. Prior to that, Bernd was VP Oncology drug discovery at Bristol-Myers Squibb and held senior faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University. For the last decade, he has successfully worked with several biotech companies and start-ups acting as CEO, director or chairman of the board. Bernd holds an MD from the Ludwig-Maximilians-University and a PhD from the Max Planck Institute of Psychiatry Munich, Germany and has published over 100 scientific papers. 


Dr. Mathieu Simon
Advisory Board
Dr. Mathieu Simon
Advisory Board

Mathieu is Chairman of Idorsia and board director at a number of public and private biotech companies. He also serves an advisor to the European Commission D.G. Research and Innovation and as Senior Strategic Advisor to Messier Maris Partners, a small international investment bank. He was Executive Vice President and Chief Operating Officer of Cellectis and, prior to that, SVP and Head of Global Pharmaceutical Operations at Pierre Fabre. He also was at Wyeth (now Pfizer) in both senior corporate and regional roles in the US and Europe. Mathieu holds a degree in internal medicine from the Faculty of Medicine, Paris VII.


Dallas Webb
Advisory Board
Dallas Webb
Advisory Board

Dallas Webb is a Portfolio Manager with BB Biotech / Bellevue Asset Management since 2006, focusing on emerging public biotech companies. Prior to that, he served as Senior Vice President and Equity Analyst at Stanford Group Company, at Sterling Financial Investment Group, and at Adams, Harkness & Hill. Dallas has an MBA from Texas Christian University in Fort Worth, Texas, and a Bachelor of Science in Microbiology and Zoology from Louisiana State University. 


Ben Morgan
General Partner Board
Ben Morgan
General Partner Board

Ben is a partner and head of the funds group at Carey Olsen in Guernsey and has significant experience advising a variety of private and public funds. Ben qualified as an English solicitor in 1992 and practiced in the City before joining Carey Olsen in 1999. Ben became an advocate in 2003 and has been a partner in the Guernsey office since 2003. Ben is also a member of the firm's London office. He currently holds a number of directorships with other fund management companies and funds. Ben has been a Director of BB Pureos Bioventures GP (Guernsey) Limited since its inception.


Karen Haith
General Partner Board
Karen Haith
General Partner Board

Karen has over two decades of experience in the financial services industry across the areas of private equity, alternative investment administration, corporate governance, risk management, tax information exchange related issues and accounting. She currently holds a number of directorships with other fund management companies and funds, and provides consultancy and training services in her field of expertise. In 2016, Karen founded the Women’s Business Network which gives networking opportunities to senior women in business in Guernsey. Karen has been a Director of BB Pureos Bioventures GP (Guernsey) Limited since its inception.


Pascal Mahieux
General Partner Board
Pascal Mahieux
General Partner Board

Pascal is a Vice President at Northern Trust in Guernsey, where he manages client relationships over multiple jurisdictions. Prior to that, he was a senior manager of several operational teams within Northern Trust’s private equity department. He is a qualified accountant with over two decades of experience in offshore fund administration. He has been a member of audit, portfolio management and risk committees and currently holds a number of directorships with other fund management companies and funds. Pascal has been a Director of BB Pureos Bioventures GP (Guernsey) Limited since its inception.


Dr. Bruno Teta
Pureos Partners Board
Dr. Bruno Teta
Pureos Partners Board

Bruno is a Director at Pureos Partners and a co-founder and Partner at Crystal Asset Management, which invests in Swiss and European equities. Bruno began his investment career in equity sales at Credit Suisse in 1994. Prior to founding Crystal in 2011, Bruno was an analyst, Head of Sales and a member of the management board of Bank am Bellevue. Bruno obtained his PhD in Business Management from the University of Zurich and is a Chartered Financial Analyst.

Dr. Matthias Staehelin
Pureos Partners Board
Dr. Matthias Staehelin
Pureos Partners Board

Matthias is a Director at Pureos Partners, Partner and co-head of Life Sciences Team at the law firm Vischer AG and notary public in Basel-City and Basel-Country. Matthias is an experienced lawyer specialized in the life sciences sector, including company acquisitions and sales (M&A), financing by private equity/venture capital investors, licensing and collaboration agreements, IPOs and restructurings. He is also president of BioValley Basel and board member of the BioValley Business Angels Club (BioBAC). Matthias has studied in Halifax, Basel, Bruges and Freiburg i.B. and has a PhD in Law from the University of Basel and a Master of Advanced European Studies from the College of Europe, Bruges.

News

Our companies and we are trying to stay at forefront of innovation with the goal to save and improve patients’ lives. We are glad to share our progress on the way to achieving this goal.

December 2021
Acrivon Therapeutics

Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders
December 2021
Hummingbird Bioscience

Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies
November 2021
Hummingbird Bioscience

Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board
November 2021
Lava Therapeutics

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 2021
ImCheck Therapeutics

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
November 2021
Pureos Bioventures

Pureos Bioventures Invests in Acrivon Therapeutics
November 2021
Araris Biotech

Araris is Expanding its Scientific Advisory Board with Dr. Jeff Sharman and Dr. Clive Stanway
November 2021
Hummingbird Bioscience

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting
November 2021
Pureos Bioventures

Pureos Bioventures Welcomes Dr. Lars Nieba to its Team as Venture Partner
November 2021
Alentis Therapeutics

Alentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaele Tordjman as Chairperson
October 2021
Hummingbird Bioscience

Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
October 2021
ImCheck Therapeutics

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
October 2021
Lava Therapeutics

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia
October 2021
Hummingbird Bioscience

Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers
September 2021
Hummingbird Bioscience

Hummingbird Bioscience Opens New Office and Research Facilities
September 2021
Pureos Bioventures

Pureos Bioventures Expands the Team by the Appointment of Venture Partners
September 2021
ImCheck Therapeutics

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
September 2021
Araris Biotech

Araris Biotech Shortlisted in Top 5 of World ADC Awards 2021 in Category “Best ADC Platform Technology“
September 2021
Hummingbird Bioscience

Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
September 2021
ImCheck Therapeutics

ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
September 2021
Araris Biotech

Araris Biotech Ranks TOP11 at Swiss Startup Award 2021
September 2021
AM-Pharma

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan
August 2021
Lava Therapeutics

LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
August 2021
Eyevensys

Eyevensys Raises $12M in a Series B Plus Funding Round
July 2021
Alentis Therapeutics

Alentis Therapeutics Raises USD 67 Million in Series B Financing
July 2021
Lava Therapeutics

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
July 2021
ImCheck Therapeutics

ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
July 2021
AM-Pharma

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board
July 2021
AM-Pharma

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial
June 2021
Corlieve Therapeutics

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
May 2021
Hummingbird Bioscience

Hummingbird Bioscience Raises US$125 Million in Series C Financing
April 2021
ImCheck Therapeutics

ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
April 2021
Pureos Bioventures

Pureos Bioventures Expands Fund Size to USD 205 Million
More News News Archive

Contact

We are looking forward to connecting with you!